Estrogen/NN
binding/NN
sites/NNS
in/IN
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
effects/NNS
of/IN
danazol/NN
on/IN
their/PRP$
sites/NNS
in/FW
vitro/FW
./.

1/LS
./.
=====
This/DT
study/NN
was/VBD
designed/VBN
to/TO
investigate/VB
the/DT
presence/NN
of/IN
estrogen/NN
type/NN
I/CD
(/(
high/JJ
affinity/NN
,/,
low/JJ
capacity/NN
)/)
and/CC
type/NN
II/CD
(/(
low/JJ
affinity/NN
,/,
high/JJ
capacity/NN
)/)
binding/NN
sites/NNS
in/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
the/DT
effects/NNS
of/IN
danazol/NN
on/IN
these/DT
sites/NNS
./.
=====
2/LS
./.
=====
These/DT
two/CD
types/NNS
of/IN
estrogen/NN
binding/NN
sites/NNS
existed/VBD
in/IN
human/JJ
peripheral/JJ
blood/NN
monocytes/NNS
./.
=====
3/LS
./.
=====
Danazol/NN
bound/VBD
to/TO
these/DT
sites/NNS
in/IN
high/JJ
concentration/NN
(/(
10/CD
(/(
-6/CD
)/)
M/NN
,/,
clinical/JJ
serum/NN
concentration/NN
during/IN
danazol/NN
therapy/NN
)/)
and/CC
decreased/VBD
the/DT
number/NN
of/IN
both/DT
sites/NNS
./.
=====
4/LS
./.
=====
It/PRP
is/VBZ
suggested/VBN
that/IN
danazol/NN
has/VBZ
an/DT
anti-estrogenic/JJ
action/NN
to/TO
the/DT
monocytes/NNS
through/IN
the/DT
competition/NN
and/CC
suppression/NN
of/IN
estrogen/NN
binding/NN
sites/NNS
as/IN
seen/VBN
in/IN
the/DT
estrogen/NN
target/NN
organ/NN
./.